Format
Items per page
Sort by

Send to:

Choose Destination

Results: 15

Related Articles by Review for PubMed (Select 23661171)

1.

CYP2C19 genotypes and their impact on clopidogrel responsiveness in percutaneous coronary intervention.

Mejin M, Tiong WN, Lai LY, Tiong LL, Bujang AM, Hwang SS, Ong TK, Fong AY.

Int J Clin Pharm. 2013 Aug;35(4):621-8. doi: 10.1007/s11096-013-9783-y. Epub 2013 May 10.

PMID:
23661171
2.

[Genetic variability in the efficacy of clopidogrel].

Kristensen KE, Rasmussen HB, Hansen PR.

Ugeskr Laeger. 2013 Mar 11;175(11):729-32. Review. Danish.

PMID:
23480885
3.

CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis.

Holmes MV, Perel P, Shah T, Hingorani AD, Casas JP.

JAMA. 2011 Dec 28;306(24):2704-14. doi: 10.1001/jama.2011.1880. Review.

PMID:
22203539
4.

Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis.

Bauer T, Bouman HJ, van Werkum JW, Ford NF, ten Berg JM, Taubert D.

BMJ. 2011 Aug 4;343:d4588. doi: 10.1136/bmj.d4588. Review.

5.

Cytochrome P450 2C19 polymorphism and antiplatelet therapy. Who should really be genotyped?

Kassimis G, Stavrou EF, Alexopoulos D, Athanassiadou A.

Curr Pharm Des. 2013;19(13):2489-95. Review.

PMID:
23360266
6.

The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y(12) inhibitors.

Price MJ, Tantry US, Gurbel PA.

Rev Cardiovasc Med. 2011;12(1):1-12. doi: 10.3909/ricm0590. Review.

PMID:
21546883
7.

Genetic and nongenetic factors influencing the response to clopidogrel.

Notarangelo MF, Bontardelli F, Merlini PA.

J Cardiovasc Med (Hagerstown). 2013 Dec;14 Suppl 1:S1-7. doi: 10.2459/JCM.0b013e328364bb04. Review.

PMID:
24378836
8.

Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel.

Zabalza M, Subirana I, Sala J, Lluis-Ganella C, Lucas G, Tomás M, Masiá R, Marrugat J, Brugada R, Elosua R.

Heart. 2012 Jan;98(2):100-8. doi: 10.1136/hrt.2011.227652. Epub 2011 Jun 21. Review.

PMID:
21693476
9.

Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations.

Ellis KJ, Stouffer GA, McLeod HL, Lee CR.

Pharmacogenomics. 2009 Nov;10(11):1799-817. doi: 10.2217/pgs.09.143. Review.

PMID:
19891556
10.

Potential clinical utility of genetic and platelet function tests in patients on treatment with clopidogrel.

Cattaneo M.

J Cardiovasc Med (Hagerstown). 2013 Dec;14 Suppl 1:S16-21. doi: 10.2459/JCM.0b013e328364bd3a. Review.

PMID:
24378837
11.

Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy.

Scott SA, Sangkuhl K, Gardner EE, Stein CM, Hulot JS, Johnson JA, Roden DM, Klein TE, Shuldiner AR; Clinical Pharmacogenetics Implementation Consortium.

Clin Pharmacol Ther. 2011 Aug;90(2):328-32. doi: 10.1038/clpt.2011.132. Epub 2011 Jun 29. Review. No abstract available.

12.

Pharmacogenomics of anti-platelet therapy: how much evidence is enough for clinical implementation?

Perry CG, Shuldiner AR.

J Hum Genet. 2013 Jun;58(6):339-45. doi: 10.1038/jhg.2013.41. Epub 2013 May 23. Review.

13.

Clinical consequences of aspirin and clopidogrel resistance: an overview.

Mijajlovic MD, Shulga O, Bloch S, Covickovic-Sternic N, Aleksic V, Bornstein NM.

Acta Neurol Scand. 2013 Oct;128(4):213-9. doi: 10.1111/ane.12111. Epub 2013 Feb 21. Review.

PMID:
23432706
14.

Poor metabolizers at the cytochrome P450 2C19 loci is at increased risk of developing cancer in Asian populations.

Wang H, Song K, Chen Z, Yu Y.

PLoS One. 2013 Aug 27;8(8):e73126. doi: 10.1371/journal.pone.0073126. eCollection 2013. Review.

15.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk